HLS Therapeutics Sees FY2026 Sales $56.000M-$60.000M vs $57.730M Est
HLS Therapeutics (TSX:HLS) sees FY2026 sales of $56.000 million-$60.000 million vs $57.730 million analyst estimate.
Read original at benzingaStocks · News reference
HLS Therapeutics Q2 EPS $(0.03) Beats $(0.10) Estimate, Sales $14.673M Beat $14.467M Estimate
HLS Therapeutics (TSX:HLS) reported quarterly losses of $(0.03) per share which beat the analyst consensus estimate of $(0.10) by 70 percent. This is a 66.67 percent increase over losses of $(0.09) per share from the
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 12, 2026, 10:34 AM
- Checked
- Aug 12, 2026, 10:34 AM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading